Recent studies using DuPont’s HOWARU strain combination, combined with a better understanding of ‘the rules of the game’, will lead to positive health claims in Europe, DuPont’s Scott Bush has confidently predicted.
Mr Bush, VP Marketing - Nutrition and Health, DuPont told NutraIngredients-USA at SupplySide West in Vegas that, “while [the EFSA health claims process] been a hurdle for the probiotics industry, I fully anticipate that down the road DuPont and other companies investing heavily in probiotic science will get claims approved.”
Bush talked about the results of a new study using the company’s Howaru probiotic blend for antibiotic-related diarrhea.
“We showed very significant results with both the 1 and 10 billion doses, versus the placebo, in terms of reduction of incidence, reduction in the duration of antibiotic-associated diarrhea, and in terms of gastrointestinal symptoms.”
Bush noted that the company is now working on a gut microflora study to identify the impact of the interventions on the microflora.
So will this lead to a positive health claim in Europe?
“We’ll take the pilot study we did, coupled with this much larger study we have just finished, plus two other studies we’re just launching, and we’ll put together a compendium of those results, and I fully expect that these will lead to some EFSA claims approvals.”